Key result
US HCM mortality drops ~52% from 1999 to 2019.
Why the study?
HCM-related mortality has been decreasing in the United States, but persistent disparities across demographic subsets may exist.
Population
39 200 HCM-related deaths among people ≥15 years of age in the United States
Comparison
Demographic (sex, race and ethnicity, age) and regional groups
Design
Cross-sectional analysis of the CDC WONDER database
Authors
Loading...
Declining US HCM mortality supports care advances; extends prior trends but leaves open disparity mechanisms.
Cross-Sectional
Hypertrophic cardiomyopathy-related mortality in the United States decreased by more than half between 1999 and 2019, though significant demographic and geographic disparities persist.
Minhas et al. (2022) conducted a cross-sectional in Hypertrophic cardiomyopathy. The United States population experienced a decrease in hypertrophic cardiomyopathy-related age-adjusted mortality from 11.2 per 1,000,000 people in 1999 to 5.4 per 1,000,000 people in 2019.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: